SLRN Insider Trading Activity and SEC Form 4 Filings
SLRN insider trading summary
No open-market insider purchases or sales of ACELYRIN, Inc. (SLRN) have been reported on SEC Form 4 in the past 12 months.
Latest SLRN insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Mar 17, 2025 | Shephard Mpofu | Chief Medical Officer | Sell | $9K (3,211 @ $2.74) |
| Mar 17, 2025 | Amar Murugan | Chief Legal Officer | Sell | $11K (3,913 @ $2.74) |
| Mar 17, 2025 | Mina Kim | Chief Executive Officer | Sell | $49K (17,986 @ $2.74) |
| Jul 17, 2024 | Daniel J. Becker | Director | Sell | $7 (1 @ $6.86) |
| Apr 1, 2024 | Shao-Lee Lin | Chief Executive Officer | Sell | $66K (9,961 @ $6.63) |
| Feb 20, 2024 | Shao-Lee Lin | Chief Executive Officer | Sell | $119K (15,701 @ $7.60) |
| Jan 2, 2024 | Shao-Lee Lin | Chief Executive Officer | Sell | $79K (10,691 @ $7.41) |
| May 9, 2023 | Beth C Seidenberg | Director | Buy | $22.5M (1,250,000 @ $18.00) |
| May 9, 2023 | Mardi Dier | CFO and CBO | Buy | $100K (5,556 @ $18.00) |
| May 9, 2023 | Westlake BioPartners Fund II, L.P. | 10% Owner | Buy | $22.5M (1,250,000 @ $18.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.